# Effect of Tirzepatide on Recurrence of Atrial Fibrillation After Catheter Ablation in Obese Patients

Study · id `cardio:ct-nct07715929` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07715929](<https://clinicaltrials.gov/study/NCT07715929>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07715929

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 710 participants.

## Technical summary

Registry record NCT07715929. Randomized; single masking; primary purpose treatment. Start 2026-09-01 (anticipated); primary completion 2029-09-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 710 participants (planned count; ClinicalTrials.gov record NCT07715929, source copy `cardio:ctgov-nct07715929-2026-07-21`, retrieved 2026-10-26)
- Planned start: 2026-09-01 (anticipated) (ClinicalTrials.gov record NCT07715929, source copy `cardio:ctgov-nct07715929-2026-07-21`, retrieved 2026-10-26)
- Primary completion: 2029-09-01 (anticipated) (ClinicalTrials.gov record NCT07715929, source copy `cardio:ctgov-nct07715929-2026-07-21`, retrieved 2026-10-26)
- Completion: 2029-12-30 (anticipated) (ClinicalTrials.gov record NCT07715929, source copy `cardio:ctgov-nct07715929-2026-07-21`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07715929-2026-07-21`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effect of Tirzepatide on Recurrence of Atrial Fibrillation After Catheter Ablation in Obese Patients
- Acronym: TEAR-AF
- Condition: Atrial Fibrillation
- Condition: Obesity & Overweight
- Condition: Catheter Ablation
- Intervention (Drug): Tirzepatide
- Intervention (Behavioral): Structured Lifestyle Intervention
- Lead sponsor: Yunlong Wang
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry intervention name matches this record: Tirzepatide (`cardio:tirzepatide`)

## Provenance

Content hash: 5e74c03034a187281e339f0ae2aaf42e14bffe9127066d3b7afcd0036ee97236
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
